- DexCom shares surged by 16.2% after reporting unexpectedly high first-quarter revenue.
- The company announced a $750 million stock buyback, enhancing investor sentiment.
- Analysts predict a potential upside of 21.35% with a "Strong Buy" consensus.
Shares of DexCom (DXCM, Financial) surged 16.2% following the company's announcement of robust first-quarter revenue, surpassing market expectations. Despite a minor dip in profits, the glucose monitoring device manufacturer unveiled a $750 million stock repurchase initiative, which significantly boosted investor confidence.
Wall Street Analysts Forecast
According to projections from 25 analysts, the average price target for DexCom Inc (DXCM, Financial) over the next year is $99.04. The forecasts range from a high of $115.00 to a low of $82.00, indicating an anticipated growth potential of 21.35% from the current trading price of $81.62. For further insights, visit the DexCom Inc (DXCM) Forecast page.
The consensus recommendation from 27 brokerage firms for DexCom Inc (DXCM, Financial) is presently at 1.7, classifying it under "Outperform." On the rating scale where 1 is a Strong Buy and 5 is a Sell, this indicates strong market confidence in the stock's performance.
GuruFocus estimates the one-year GF Value of DexCom Inc (DXCM, Financial) at $167.04, which suggests a substantial upside of 104.66% from the current price of $81.62. The GF Value signifies GuruFocus' projection of the stock's fair market value, calculated considering historical trading multiples, past business growth, and future performance estimates. For more comprehensive data, refer to the DexCom Inc (DXCM) Summary page.
